Abstract：Objective: To measure the expression levels of miR-142-5p in the hepatocellular carcinoma (HCC) tissues and plasma; to explore the correlation of miR-142-5p with pathological characteristics of HCC; and to predict the target genes of miR-142-5p. Methods: A total of 40 HCC patients associated with hepatitis B virus (HBV), and 35 patients with chronic hepatitis B (CHB) were enrolled in this study. Expression levels of miR-142-5p in HCC specimens, paracancerous specimens and plasma of HCC patients were detected. The correlation of miR-142-5p with pathological characteristics of HCC was analyzed. The receiver operating curve (ROC) was plotted to identify the diagnostic potential of miR-142-5p in HCC. The target genes of miR-142-5p were predicted by bioinformatics. Results: MiR-142-5p was significantly lowly expressed in HCC specimens than the paracancerous specimens. Plasma miR-142-5p was positively correlated with the expression level of miR-142-5p in HCC specimens, and both of them were significantly lower in CHB patients. Expression level of miR-142-5p in HCC specimens and its plasma level in HCC patients were significantly correlated with the differentiation level and BCLC staging system of HCC. The ROC analysis suggested the diagnostic potential of miR-142-5p in HCC. The area under the curve (AUC) of miR-142-5p in HCC specimens and plasma miR-142-5p in diagnosing HCC was 0.692 and 0.755, respectively. Bioinformatics showed 16 target genes of miR-142-5p cross-existed in 6 databases. Furthermore, GO and KEGG analyses showed that miR-142-5p was involved in the occurrence and progression of HCC through multiple pathways. Conclusion: MiR-142-5p is a potential biomarker for the diagnosis of HCC, which is closely related to the occurrence and development of HCC.
[1] Li H,Li HH,Chen Q,et al.miR-142-5p inhibits cell invasion and migration by targeting DNMT1 in breast cancer.[J].Oncol Res,2022,28(9):885-897. [2] Zhang Q,Liu H,Zhang J,et al.MiR-142-5p suppresses lung cancer cell metastasis by targeting yin yang 1 to regulate epithelial-mesenchymal transition[J].Cell Reprogram,2020,22(6):328-336. [3] Yao R,Xu L,Wei B,et al.miR-142-5p regulates pancreatic cancer cell proliferation and apoptosis by regulation of RAP1A[J].Pathol Res Pract,2019,215(6):152416-152416. [4] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南年版[J].中华传染病杂志,2023,41(1):3-28. [5] 中华人民共和国国家卫生健康委员会医政司.原发性肝癌诊疗指南年版[J].协和医学杂志,2024,15(03):532-559. [6] Xu L,Tian L,Yan Z,et al.Diagnostic and prognostic value of miR-486-5p,miR-451a,miR-21-5p and monocyte to high-density lipoprotein cholesterol ratio in patients with acute myocardial infarction[J].Heart Vessels,2023,38(3):318-331. [7] Forner A,Reig M E,de Lope C R,et al.Current strategy for staging and treatment:the BCLC update and future prospects[J].Semin Liver Dis,2010,30(1):61-74. [8] Zhu Q,Gong L,Wang J,et al.miR-10b exerts oncogenic activity in human hepatocellular carcinoma cells by targeting expression of CUB and sushi multiple domains 1 (CSMD1)[J].BMC Cancer,2016,16(1):806-806. [9] Sun Y,Shi P,Wu Q,et al.MiR-222-3p induced by hepatitis B virus promotes the proliferation and inhibits apoptosis in hepatocellular carcinoma by upregulating THBS1[J].Hum Cell,2021,34(6):1788-1799. [10] An F,Wu X,Zhang Y,et al.miR-224 regulates the aggressiveness of hepatoma cells through the IL-6/STAT3/SMAD4 pathway[J].Turk Gastroenterol,2021,32(6):532-542. [11] Badr AM,El-Ahwany E,Goda L,et al.MicroRNA-26a systemic administration attenuates tumor formation in hepatocellular carcinoma mouse model[J].Pak Pharm Sci,2021,34(3):925-932. [12] Shehab-Eldeen S,Metwaly MF,Saber SM,et al.MicroRNA-29a and MicroRNA-124 as novel biomarkers for hepatocellular carcinoma[J].Dig Liver Dis,2023,55(2):283-290. [13] Lou K,Chen N,Li Z,et al.MicroRNA-142-5p overexpression inhibits cell growth and induces apoptosis by regulating FOXO in hepatocellular carcinoma cells[J].Oncol Res,2017,25(1):65-73. [14] Guo YJ,Pan WW,Liu SB,et al.ERK/MAPK signalling pathway and tumorigenesis[J].Exp Ther Med,2020,19(3):1997-2007.
2025, Vol. 31 
冀公网安备13080202000786号